ADITXT INC (ADTX)       0.86  -0.03 (-3.09%)

Company Profile

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The company is headquartered in Richmond, Virginia and currently employs 58 full-time employees. The company went IPO on 2020-06-19. The firm is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.

Company Info

ADITXT INC

737 N. Fifth Street, Suite 200

Richmond VIRGINIA 94043

P: 19094880844.0

CEO: Amro Albanna

Employees: 58

Website: https://aditxt.com/